Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
about
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor bindingCloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyteInterleukin 1 receptor antagonist. A new member of the interleukin 1 familyPhenotypic characteristics of human monocytes undergoing transendothelial migrationVLA-4-dependent and -independent pathways in cell contact-induced proinflammatory cytokine production by synovial nurse-like cells from rheumatoid arthritis patientsProinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodiesImportance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cellsRANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapiesInterleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanismAsthma and the Risk of Rheumatoid Arthritis: An Insight into the Heterogeneity and Phenotypes of AsthmaAnakinra treatment of patients with rheumatoid arthritis.Regulation of synovial cell apoptosis by proteasome inhibitor.Upregulation of insulin-like growth factor I gene expression in the lesions of osteoarthritic human articular cartilageDetermination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue.Bone mass in patients with rheumatoid arthritis.Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine.Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity.Increased type I collagen degradation correlates with disease severity in rheumatoid arthritisAntifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis.Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study.Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone.Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies.Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I.Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.Infection of human synovial cells by human T cell lymphotropic virus type I. Proliferation and granulocyte/macrophage colony-stimulating factor production by synovial cellsCurrent evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis.Conjugated linoleic acid and bone biology.Periodontal status of rheumatoid arthritis patients in khartoum stateMacrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis.Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.Evaluation of Protective Efficacy of Avicennia marina (Forssk.) Vierh Leaves against Complete Freund᾽s Adjuvant-induced Arthritis in Wistar.JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Ganglioside GM3 has an essential role in the pathogenesis and progression of rheumatoid arthritis.Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2.Raised pro-inflammatory cytokines interleukin 6 and tumour necrosis factor alpha in coeliac disease mucosa detected by immunohistochemistry.Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology.The identification of CD163 expressing phagocytic chondrocytes in joint cartilage and its novel scavenger role in cartilage degradation.
P2860
Q24291729-23ECC45C-AD66-4ACC-BC6B-A84B65549DEEQ24304897-E25029F2-148D-4088-801F-5B1D13123712Q24630432-385C7386-1113-4EBB-9B56-FBA5702E8E42Q24793076-F6EF5E60-6939-4A93-8A31-312FE2BE5F0EQ24793818-84FFB93D-F1F2-4CED-A999-01258F3B1936Q24803611-69440D65-B0DB-47B9-A070-82236B1DB8B8Q28366784-480CB13D-1420-4B15-9D7E-B57F3355CBA6Q28570898-19DC56CC-A3E1-40FB-BBCC-56E77C9AD6E4Q28571336-3AF25B3F-6761-415D-B445-50FB67A88E3BQ30234766-29CE2DB6-03F5-4D46-A637-D2C63AB19A67Q31089069-8EC49D52-9FEE-49A6-9D96-6C7796BA494CQ33179130-1ECA8EEB-4181-4420-BC5E-C1CCD4AB4D76Q33564495-D7745CBE-4A9E-4AD0-8349-D1907AD3E084Q33564673-88EA5506-7F64-4864-879A-E9A8DC38F1D8Q33564801-C034EB72-EF78-4FDB-8769-41B4E354D8ECQ33564938-51D2B886-9320-450A-AEBD-6AA5F1AD8DDCQ33565191-65374212-547E-424F-BA31-9BE07BE5F60FQ33565980-C5FCBD79-B0E9-4B51-9616-F094D729388FQ33578174-0D69EACF-87A0-48EA-81F0-C9280287D9E4Q33578257-B1EECA27-9391-43D1-927D-ABD97F04A798Q33578415-826822A9-59B0-4416-9AA5-AB6B04EEC723Q33578511-C7B86A0D-E6D8-4B52-B548-2A530BBE3390Q33578993-F9C2A550-EEDF-4A98-A517-B09051214B69Q33655250-9829970C-9397-46DA-A2C7-8D8B6983B5DFQ33782360-C968921E-FD16-40AE-A40B-8C571EEEFA30Q33905638-195668F5-A274-49BF-80BB-9BA1B7B092E4Q33973488-A9F2663E-53E1-4A10-A9A3-A105B71E96B1Q34001731-1025382F-5B54-4682-9D41-3848794E7A44Q34017277-487CBA7B-7861-49D6-A447-FC0C62260ED0Q34060781-49945BA8-75CE-4AA2-9C1F-E481E4C76865Q34129985-BE1764F0-4E82-4E27-BD7F-D6F87219863DQ34236293-D28C8517-AA0C-47E5-8377-3ED5BF0F0B02Q34251859-1A2F3609-D444-4E0F-AD51-1EBABE7DC342Q34256337-708F58A6-3C22-412A-84CB-A558DF62837AQ34276089-9B5C6926-6857-439B-B63B-9B8F134BD1BAQ34328705-BB19B628-EA71-4C9E-B3C4-336DB9CBF17EQ34364832-0D75912C-FD3C-4042-BD48-3AB23E3371D2Q34379763-EC3C1C83-685F-4400-977F-AAB95E8F49C8Q34402915-24B38835-1537-4053-931E-119980E4712AQ34551313-5F17B914-B7EF-4EFC-A7E7-9F7ED65438FE
P2860
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
@en
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
@nl
type
label
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
@en
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
@nl
prefLabel
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
@en
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
@nl
P356
P1476
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.
@en
P2093
P304
P356
10.1002/ART.1780330302
P577
1990-03-01T00:00:00Z